# OMass Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omass-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.omass.com
- Total disclosed funding: $511M
- Latest round: Series C (Oct 15, 2026)
- Investors on record: 15

## About

Based in the UK, OMass Therapeutics Limited is a biotechnology company focused on developing innovative small molecule therapeutics for orphan diseases and immunological conditions, utilizing advanced biochemistry techniques.OMass Therapeutics Limited specializes in the development of small molecule therapeutics. Founded in 2016, the company is headquartered in Oxford, UK. It was co-founded by Idlir Liko and Jonathan Hopper, with Ros Deegan serving as the CEO. OMass has successfully completed five deals, with the most recent funding round being a Series B in May 2023, raising GBP 10 million from British Patient Capital. The total amount raised by the company is GBP 10 million.OMass Therapeutics specializes in developing small molecule therapeutics aimed at treating orphan diseases and immunological conditions. Their product portfolio focuses on validated target ecosystems, such as membrane proteins and intracellular complexes, employing advanced biochemistry, native mass spectrometry, and custom chemistry techniques. Their therapeutics primarily serve patients with immunological disorders and rare diseases that are not adequately treated by existing solutions. OMass operates in Europe, North America, and Asia, targeting healthcare providers, pharmaceutical companies, and research institutions for its innovative therapeutic solutions.In 2023, OMass Therapeutics reported no revenue, with an EBITDA loss of GBP 28,579,921. The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, often involving licensing and collaborative agreements for developing new therapeutics. Revenue streams include milestone payments and royalties from eventual product sales.OMass Therapeutics intends to utilize the GBP 10 million raised in May 2023 for its clinical development and pipeline expansion. The company is focused on introducing new products designed to meet unmet medical needs in immunological conditions and orphan diseases. As part of its growth strategy, OMass plans to expand its market reach in Europe, North America, and Asia, aiming for increased engagement with healthcare providers and pharmaceutical companies within these regions.

## Funding rounds

- Series C, Oct 15, 2026, $310M — Forbion, Novo Holdings, Bain Capital Life Sciences, Janus Henderson Investors, Jefferson Life Sciences, Northpond Ventures, Oxford Science Enterprises, Sanofi Ventures, SV Health Investors, Syncona, University of Oxford, British Business Bank, GV
- Series B, Apr 18, 2023, $50M — GV, Sanofi Ventures, Syncona, Oxford Sciences Enterprises, British Patient Capital, Northpond Ventures
- Series B, Apr 27, 2022, $95M — GV, Sanofi Ventures, Syncona, Oxford Sciences Enterprises, Northpond Ventures
- Series A, Feb 13, 2020, $36M — Syncona, University of Oxford, Oxford Sciences Enterprises
- Series A, Jun 29, 2018, $18M — Syncona, Oxford Sciences Enterprises
- Seed, Mar 24, 2016, $1.6M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A, Series B
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B, Series C
- University of Oxford — Series A, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B, Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B, Series C
- British Patient Capital — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Novo Holdings — Series C
- Bain Capital Life Sciences — Series C
- Janus Henderson Investors — Series C
- Jefferson Life Sciences (https://capitalatlas.ai/funds/jefferson-life-sciences) — Series C
- Oxford Science Enterprises — Series C
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series C
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series C